Safety Study of ExAblate for the Treatment of Uterine Fibroids

Completed · Not applicable

Conditions studied: Uterine Fibroids

In brief

The objective of this Phase IV study is to evaluate the safety of the ExAblate treatment of uterine fibroids using the enhanced sonication techniques, based on the current commercially-approved treatment guidelines. Treatment may include up to 100% of individual fibroid volume, within established serosal and sacral treatment margins. The Enhanced sonication is one of the various sonication modes that may lead to increased thermal dose volume of each sonication without additional safety risks. This is an additional treatment tool available in the ExAblate system for the treatment of uterine fibroids. The safety profile of the Enhanced Sonication was investigated under an FDA-regulated IDE study. FDA granted approval of Enhanced Sonication with the requirement to perform a post-approval study to collect additional safety data when treating up to 100% of individual fibroid volume.

Key facts

Study ID

NCT01142791

Run by

InSightec

People needed

121

Starts

2010-05-01

Expected to finish

2012-04-01

Last updated by the study team

2019-03-19

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Women age 18 or older
• Symptomatic uterine fibroids, defined as those resulting in scores of 21 or higher, based on patient responses to questions 1-8 of the Uterine Fibroid Symptom and Health-Related Quality of Life Questionnaire (UFS-QOL)
• Women who have given written informed consent
• Women who are able and willing to attend all study visits.
• Patient is pre or peri-menopausal (within 12 months of last menstrual period).
• Patient should be family complete.
• Able to communicate sensations during the ExAblate procedure.
• Uterine fibroids, which are device accessible (i.e., positioned in the uterus such that they can be accessed without being shielded by bowel or bone).
• Fibroids(s) clearly visible on non-contrast MRI.
• Fibroid enhances on MR contrast imaging.

You may not qualify if…

• Women who are pregnant, as confirmed by serum/urine test at time of screening, or urine pregnancy test on the day of treatment.
• Patients who are breast-feeding.
• Patients with active pelvic inflammatory disease (PID).
• Patients with active local or systemic infection.
• Patients experiencing chronic leg or lower back pain within the last 6 months.
• Contraindication for MRI Scan:
• Severe claustrophobia that would prevent completion of procedure in the MR unit
• Weight greater than 250 lbs (113Kg)
• Implanted ferromagnetic materials and/or devices contraindicated for MR scan
• Known intolerance to MRI contrast agent (e.g. Gadolinium or Magnevist)
• Any other contraindication for MRI Scan
• Extensive abdominal scarring in the beam path (that cannot be avoided by redirection of the beam).
• Dermoid cyst of the ovary anywhere in the treatment path.
• Known or suspected pelvic carcinoma or pre-malignant conditions, including sarcoma and adenomatous hyperplasia.
• Intrauterine device (IUD) anywhere in the treatment path.
• Undiagnosed vaginal bleeding.
• Pedunculated fibroids.
• Uterine size >24 weeks.

Where it is running

• UCLA — Los Angeles, California, United States
• UCSD Department of Radiology — San Diego, California, United States
• University of California San Francisco — San Francisco, California, United States
• University Image Guided Therapy — Boca Raton, Florida, United States
• Borgess Research Institute — Kalamazoo, Michigan, United States
• Duke University — Durham, North Carolina, United States
• The Methodist Hospital Research Institute — Houston, Texas, United States
• University of Virginia Health System — Charlottesville, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.